Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Global Blood Therapeutics revenue
Global Blood Therapeutics's revenue is $194.7 million.
What is Global Blood Therapeutics's revenue?
- Global Blood Therapeutics's revenue growth from 2019 to 2021 is 9,138.57%.
- Global Blood Therapeutics has 457 employees, and the revenue per employee ratio is $426,146.
- Global Blood Therapeutics's peak quarterly revenue was $71.5M in 2022(q2).
- Global Blood Therapeutics peak revenue was $194.7M in 2021.
- Global Blood Therapeutics annual revenue for 2020 was 123.8M, 5,773.01% growth from 2019.
- Global Blood Therapeutics annual revenue for 2021 was 194.7M, 57.31% growth from 2020.
On this page
Zippi applies for you, and finds you a job.
Global Blood Therapeutics historical revenue
Global Blood Therapeutics's peak revenue was $194.7M in 2021. The peak quarterly revenue was $71.5M in 2022(q2).
Global Blood Therapeutics's revenue increased from $2.1m in 2019 to $194.7M currently. That's a 9,138.57% change in annual revenue.
Global Blood Therapeutics annual revenue
Global Blood Therapeutics annual revenue over time
| Fiscal year / year | Global Blood Therapeutics revenue |
|---|---|
| 2019 | $2.1M |
| 2020 | $123.8M |
| 2021 | $194.7M |
Global Blood Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Global Blood Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | - | - | - | $2.1M |
| 2020 | $14.1M | $31.5M | $36.9M | $41.3M |
| 2021 | $39.0M | $47.6M | $52.1M | $56.1M |
| 2022 | $55.2M | $71.6M | - | - |
Global Blood Therapeutics jobs nearby
Do you work at Global Blood Therapeutics?
Is Global Blood Therapeutics transparent about its revenue structure?
Global Blood Therapeutics financial information
| CEO | Ted W. Love |
| Company Type | Public |
| Employees Number | 457 |
| Date Founded | 2011 |
| Headquarters | South San Francisco, California |
| Number of Locations | 2 |
| Revenue | $194.7M |
| Net Income | -$303,091,000 |
| Gross Proft | $191.4M (2021) |
| Tax Rate | -0.0% |
| Total Assets | $939,208,000 |
| Ticker | GBT |
Global Blood Therapeutics jobs you might like
Global Blood Therapeutics financing
Global Blood Therapeutics received early financing of $40.7M on 2012-06-14.
| Series | Round size | Date |
|---|---|---|
| Series A | $40.7M | 06/2012 |
| Series B | $48M | 01/2015 |
| Post Ipo Equity | $143.8M | 02/2017 |
| Post Ipo Debt | $300M | 12/2021 |
Global Blood Therapeutics investors
| Investors | Security type |
|---|---|
| Third Rock Ventures | Series A |
| Wellington Management | Series B |
| Deerfield | Series B |
| Sabby Capital | Series B |
| RA Capital Management | Series B |
Global Blood Therapeutics revenue FAQs
Search for jobs
Global Blood Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Global Blood Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Global Blood Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Global Blood Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Global Blood Therapeutics. The data presented on this page does not represent the view of Global Blood Therapeutics and its employees or that of Zippia.
Global Blood Therapeutics may also be known as or be related to GLOBAL BLOOD THERAPEUTICS INC., Global Blood Therapeutics, Global Blood Therapeutics Inc and Global Blood Therapeutics, Inc.